136 related articles for article (PubMed ID: 37979911)
1. Glutamine synthetase and hepatocellular carcinoma.
Jiang J; Hu Y; Fang D; Luo J
Clin Res Hepatol Gastroenterol; 2023 Dec; 47(10):102248. PubMed ID: 37979911
[TBL] [Abstract][Full Text] [Related]
2. Roles of Combined Glypican-3 and Glutamine Synthetase in Differential Diagnosis of Hepatocellular Lesions.
Wasfy RE; Shams Eldeen AA
Asian Pac J Cancer Prev; 2015; 16(11):4769-75. PubMed ID: 26107238
[TBL] [Abstract][Full Text] [Related]
3. Prospective validation of an immunohistochemical panel (glypican 3, heat shock protein 70 and glutamine synthetase) in liver biopsies for diagnosis of very early hepatocellular carcinoma.
Tremosini S; Forner A; Boix L; Vilana R; Bianchi L; Reig M; Rimola J; Rodríguez-Lope C; Ayuso C; Solé M; Bruix J
Gut; 2012 Oct; 61(10):1481-7. PubMed ID: 22287594
[TBL] [Abstract][Full Text] [Related]
4. Inhibiting Glutamine-Dependent mTORC1 Activation Ameliorates Liver Cancers Driven by β-Catenin Mutations.
Adebayo Michael AO; Ko S; Tao J; Moghe A; Yang H; Xu M; Russell JO; Pradhan-Sundd T; Liu S; Singh S; Poddar M; Monga JS; Liu P; Oertel M; Ranganathan S; Singhi A; Rebouissou S; Zucman-Rossi J; Ribback S; Calvisi D; Qvartskhava N; Görg B; Häussinger D; Chen X; Monga SP
Cell Metab; 2019 May; 29(5):1135-1150.e6. PubMed ID: 30713111
[TBL] [Abstract][Full Text] [Related]
5. Concomitant use of heat-shock protein 70, glutamine synthetase and glypican-3 is useful in diagnosis of HBV-related hepatocellular carcinoma with higher specificity and sensitivity.
Moudi B; Heidari Z; Mahmoudzadeh-Sagheb H; Alavian SM; Lankarani KB; Farrokh P; Randel Nyengaard J
Eur J Histochem; 2018 Jan; 62(1):2859. PubMed ID: 29569872
[TBL] [Abstract][Full Text] [Related]
6. L-Asparaginase and inhibitors of glutamine synthetase disclose glutamine addiction of β-catenin-mutated human hepatocellular carcinoma cells.
Tardito S; Chiu M; Uggeri J; Zerbini A; Da Ros F; Dall'Asta V; Missale G; Bussolati O
Curr Cancer Drug Targets; 2011 Oct; 11(8):929-43. PubMed ID: 21834755
[TBL] [Abstract][Full Text] [Related]
7. Ammonia scavenger and glutamine synthetase inhibitors cocktail in targeting mTOR/β-catenin and MMP-14 for nitrogen homeostasis and liver cancer.
Elmetwalli A; Nageh A; Youssef AI; Youssef M; Ahmed MAE; Noreldin AE; El-Sewedy T
Med Oncol; 2023 Dec; 41(1):38. PubMed ID: 38157146
[TBL] [Abstract][Full Text] [Related]
8. Immunoexpression of Heat Shock Protein 70, Glypican 3, Glutamine Synthetase, and Beta-Catenin in Hepatocellular Carcinoma After Liver Transplantation: Association Between Positive Glypican 3 and Beta-Catenin With the Presence of Larger Nodules.
Ataide EC; Perales SR; Silva MG; Filho FC; Sparapani AC; Latuf Filho PF; Stucchi RSB; Vassallo J; Escanhoela CAF; Boin IFSF
Transplant Proc; 2017 May; 49(4):858-862. PubMed ID: 28457411
[TBL] [Abstract][Full Text] [Related]
9. Utility of an immunohistochemical panel consisting of glypican-3, heat-shock protein-70, and glutamine synthetase in the distinction of low-grade hepatocellular carcinoma from hepatocellular adenoma.
Lagana SM; Salomao M; Bao F; Moreira RK; Lefkowitch JH; Remotti HE
Appl Immunohistochem Mol Morphol; 2013 Mar; 21(2):170-6. PubMed ID: 22914605
[TBL] [Abstract][Full Text] [Related]
10. Glutamine synthetase-negative hepatocellular carcinoma has better prognosis and response to sorafenib treatment after hepatectomy.
Shao M; Tao Q; Xu Y; Xu Q; Shu Y; Chen Y; Shen J; Zhou Y; Wu Z; Chen M; Yang J; Shi Y; Wen T; Bu H
Chin Med J (Engl); 2023 Sep; 136(17):2066-2076. PubMed ID: 37249521
[TBL] [Abstract][Full Text] [Related]
11. Glutamine synthetase limits β-catenin-mutated liver cancer growth by maintaining nitrogen homeostasis and suppressing mTORC1.
Dai W; Shen J; Yan J; Bott AJ; Maimouni S; Daguplo HQ; Wang Y; Khayati K; Guo JY; Zhang L; Wang Y; Valvezan A; Ding WX; Chen X; Su X; Gao S; Zong WX
J Clin Invest; 2022 Dec; 132(24):. PubMed ID: 36256480
[TBL] [Abstract][Full Text] [Related]
12. Correlation between beta-catenin mutations and expression of Wnt-signaling target genes in hepatocellular carcinoma.
Austinat M; Dunsch R; Wittekind C; Tannapfel A; Gebhardt R; Gaunitz F
Mol Cancer; 2008 Feb; 7():21. PubMed ID: 18282277
[TBL] [Abstract][Full Text] [Related]
13. Glutamine synthetase mediates sorafenib sensitivity in β-catenin-active hepatocellular carcinoma cells.
Sohn BH; Park IY; Shin JH; Yim SY; Lee JS
Exp Mol Med; 2018 Jan; 50(1):e421. PubMed ID: 29303508
[TBL] [Abstract][Full Text] [Related]
14. Glutamine synthetase immunostaining correlates with pathologic features of hepatocellular carcinoma and better survival after radiofrequency thermal ablation.
Dal Bello B; Rosa L; Campanini N; Tinelli C; Torello Viera F; D'Ambrosio G; Rossi S; Silini EM
Clin Cancer Res; 2010 Apr; 16(7):2157-66. PubMed ID: 20233882
[TBL] [Abstract][Full Text] [Related]
15. Improving pathological early diagnosis and differential biomarker value for hepatocellular carcinoma via RNAscope technology.
Bakheet AMH; Zhao C; Chen JN; Zhang JY; Huang JT; Du Y; Gong LP; Bi YH; Shao CK
Hepatol Int; 2020 Jan; 14(1):96-104. PubMed ID: 31832976
[TBL] [Abstract][Full Text] [Related]
16. β-Catenin signaling in hepatocellular cancer: Implications in inflammation, fibrosis, and proliferation.
Lee JM; Yang J; Newell P; Singh S; Parwani A; Friedman SL; Nejak-Bowen KN; Monga SP
Cancer Lett; 2014 Feb; 343(1):90-7. PubMed ID: 24071572
[TBL] [Abstract][Full Text] [Related]
17. Glutamine depletion by crisantaspase hinders the growth of human hepatocellular carcinoma xenografts.
Chiu M; Tardito S; Pillozzi S; Arcangeli A; Armento A; Uggeri J; Missale G; Bianchi MG; Barilli A; Dall'Asta V; Campanini N; Silini EM; Fuchs J; Armeanu-Ebinger S; Bussolati O
Br J Cancer; 2014 Sep; 111(6):1159-67. PubMed ID: 25072259
[TBL] [Abstract][Full Text] [Related]
18. New targets of beta-catenin signaling in the liver are involved in the glutamine metabolism.
Cadoret A; Ovejero C; Terris B; Souil E; Lévy L; Lamers WH; Kitajewski J; Kahn A; Perret C
Oncogene; 2002 Nov; 21(54):8293-301. PubMed ID: 12447692
[TBL] [Abstract][Full Text] [Related]
19. Glutamine synthetase as an early marker for hepatocellular carcinoma based on proteomic analysis of resected small hepatocellular carcinomas.
Long J; Lang ZW; Wang HG; Wang TL; Wang BE; Liu SQ
Hepatobiliary Pancreat Dis Int; 2010 Jun; 9(3):296-305. PubMed ID: 20525558
[TBL] [Abstract][Full Text] [Related]
20. Immunohistochemical characteristics of hepatocellular carcinoma in non-cirrhotic livers.
Witjes CD; ten Kate FJ; Verhoef C; de Man RA; IJzermans JN
J Clin Pathol; 2013 Aug; 66(8):687-91. PubMed ID: 23585667
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
